Skip to main content
Monday, November 16, 2026Nov 16

Cleaveland: Are price controls for prescription drugs necessary?

The SafeSEAL(TM) antimicrobial soft diaphram slips onto any stethoscope effortlessly. Changed only once a week, SafeSEAL(TM)  helps provide protection against harmful bacteria commonly found on stethoscopes. Available in adult, pediatric and infant sizes. (PRNewsFoto)
The SafeSEAL(TM) antimicrobial soft diaphram slips onto any stethoscope effortlessly. Changed only once a week, SafeSEAL(TM) helps provide protection against harmful bacteria commonly found on stethoscopes. Available in adult, pediatric and infant sizes. (PRNewsFoto)
photo Dr. Clif Cleaveland

In 2001, a 5 milliliter, multi-dose vial of Acthar Gel cost $40. In March 2017, the same vial costs more than $37,000, making it the most expensive drug in the U.S.

In 1957, a trademark was granted to Armour Pharmaceuticals for Acthar. The drug was manufactured by separating and purifying adrenocorticotropic hormone (ACTH) from hog pituitary glands. ACTH is vital to human metabolism as it stimulates the release of glucocortico-steroids by the adrenal glands.

Acthar was approved initially for multiple indications. The drug proved effective in the treatment of infantile spasms (IS) in infants. This rare, complex disorder is diagnosed in up to 2,000 infants each year. Onset is typically between age 3 months to 6 months. Increasingly frequent bobbing motions of the head progress to generalized spasms. A characteristic pattern is seen on electroencephalograms. Up to one-third of afflicted children die by age 3. A large majority of victims are at risk for significant intellectual impairment. (For a full description, consult www.childneurologyfoundation.org/disorders/infantile-spasms.)

Acthar, administered by daily injection over a period of weeks to months, often controls the symptoms of IS. It is one of only two drugs approved for treatment of IS. Acthar is also approved for treating severe flares of multiple sclerosis.

Aventis Pharms acquired the rights to Acthar before selling these rights to Questor Pharmaceuticals in 2001. By 2013, the retail cost of a vial of Acthar had risen to $28,000. The drug accounted for more than $750 million in sales in 2014 and was Questor’s leading product.